CSL (CSLLY) AI Stock Analysis

Compare

56 Followers

Top Page

CSL

(OTC:CSLLY)

Rating:77Outperform

Price Target:

$99.00

▲(16.33% Upside)

CSL's strong financial performance and positive earnings guidance are key strengths, supporting a solid stock score. Technical indicators suggest caution due to overbought conditions, while valuation remains a concern with a high P/E ratio. Overall, the company's growth prospects and financial stability are well-regarded, though attention to competitive pressures and leverage is advised.

CSL (CSLLY) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$82.40B

Dividend Yield1.57%

Average Volume (3M)3.37K

Price to Earnings (P/E)30.0

Beta (1Y)0.47

Revenue Growth7.60%

EPS Growth9.47%

CountryUS

Employees32,698

SectorHealthcare

Sector Strength38

IndustryBiotechnology

Share Statistics

EPS (TTM)2.07

Shares Outstanding968,424,260

10 Day Avg. Volume0

30 Day Avg. Volume3,372

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap1.18

Enterprise Value/Revenue6.49

Enterprise Value/Gross Profit13.20

Enterprise Value/Ebitda19.52

Forecast

1Y Price Target

$86.00

Price Target Upside1.06% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering0

CSL Business Overview & Revenue Model

Company DescriptionCSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

How the Company Makes MoneyCSL Limited generates revenue primarily through the sale of its biotherapeutic and vaccine products. Its major revenue streams include plasma-derived therapies such as immunoglobulins, albumin, and coagulation factors that treat conditions like hemophilia and immune deficiencies. Additionally, its Seqirus segment contributes significantly to revenue through the production and distribution of influenza vaccines. The company benefits from strategic partnerships and collaborations that enhance its research and development capabilities, allowing it to innovate and expand its product offerings. CSL's earnings are also influenced by its extensive global distribution network and its ability to leverage economies of scale in manufacturing.

CSL Earnings Call Summary

Earnings Call Date:Feb 11, 2025

(Q2-2025)

% Change Since: 6.12%|

Next Earnings Date:Aug 18, 2025

Earnings Call Sentiment Neutral

The earnings call presented a balanced view of CSL's financial performance. Strong growth in CSL Behring and CSL Vifor, along with successful regulatory milestones, were offset by challenges in CSL Seqirus due to declining vaccination rates and increased competition in Europe. Overall, the call reflects a stable performance with a positive outlook for revenue growth.

Q2-2025 Updates

Positive Updates

Strong Revenue Growth

CSL reported revenue of AUD 8.5 billion, up 5% at constant currency with NPATA expected to grow by 10% to 13% for fiscal year 2025.

CSL Behring Performance

The CSL Behring business achieved a strong growth of 10%, driven by a 15% increase in the Ig franchise and a 9% increase in the albumin portfolio, with gross margin up 170 basis points.

CSL Vifor Growth

CSL Vifor's revenue increased by 6%, with FERINJECT showing volume growth of 6% in Europe and solid performance in nephrology segment.

Rika Platform Rollout

The rollout of Rika plasmapheresis machines is well advanced with 220 centers operating and iNomi technology implemented, increasing donor yields by around 10%.

Positive Regulatory Milestones

Garadacimab branded as ANDEMBRY received regulatory approvals in Australia and the UK, with a positive CHMP recommendation in Europe and US FDA acceptance.

Negative Updates

CSL Seqirus Revenue Decline

CSL Seqirus experienced a 9% decline in revenue due to a significant drop in influenza immunization rates in the US, particularly in the 18 to 64 age cohort.

KCENTRA Sales Decline

Specialty products saw a decline of 5%, with KCENTRA sales down 20% due to the loss of a substantial contract.

Competitive Pressures in Europe

The presence of generic competition in Europe led to pricing pressures in the iron portfolio, affecting margins despite volume growth.

Increased General and Admin Costs

General and admin costs increased by 27% compared to the prior period, largely due to one-off project costs.

Company Guidance

In the first half of fiscal year 2025, CSL Limited reported solid financial results, reaffirming their guidance for NPATA growth of 10% to 13% for the fiscal year. Revenue increased by 5% at constant currency to AUD 8.5 billion, with NPATA reaching AUD 2.1 billion, up 5%. The net profit after tax was AUD 2 billion, reflecting a 7% increase. The CSL Behring business grew by 10%, driven primarily by a 15% increase in their Ig franchise and a 9% growth in their albumin portfolio, particularly in China. Despite challenges in the U.S. market affecting CSL Seqirus, the company secured several pandemic tenders for avian flu, with most revenue expected in the second half. CSL Vifor also showed a 6% revenue increase, supported by strong performances in iron and nephrology. CSL Behring's gross margin improved by 170 basis points, attributed to efficiency enhancements and the rollout of Rika plasmapheresis machines. The company's annual guidance includes expected revenue growth of 5% to 7% and NPATA between AUD 3.2 billion to AUD 3.3 billion at constant currency, marking a 10% to 13% growth.

CSL Financial Statement Overview

Summary

CSL showcases strong financial health with significant revenue growth and stable profitability. The balance sheet is sound with a robust equity base, though leverage remains a concern. Cash flow generation is healthy, supporting future investments. Overall, CSL's financial stability and growth trajectory are solid.

Income Statement

Very Positive

CSL has demonstrated strong revenue growth with a remarkable increase from $5.95B in 2019 to $14.69B in 2024. The gross profit margin has consistently been healthy, maintaining above 50% over the years, while the net profit margin has shown resilience, peaking at 18% in the most recent year. EBIT and EBITDA margins indicate solid operational efficiency. The company's ability to grow revenues and maintain stable margins underscores its competitive positioning in the biotechnology industry.

Balance Sheet

Positive

The balance sheet reflects a robust equity base with stockholders' equity increasing considerably to $17.33B. The debt-to-equity ratio is manageable, though leverage has increased, which may pose some financial risks if earnings do not continue to grow. The equity ratio has shown stability, supporting the company's capacity to leverage its assets effectively. Overall, CSL's balance sheet is strong but could benefit from reduced leverage.

Cash Flow

Very Positive

CSL's cash flow statement reveals a healthy operating cash flow, consistently growing over the years. The free cash flow has also increased, indicating effective capital expenditure management. The operating cash flow to net income ratio suggests that cash generation is well-aligned with reported earnings, improving financial stability. The company is in a solid cash position to support its growth initiatives.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	14.69B	13.17B	10.49B	10.33B	9.41B
Gross Profit	7.56B	9.47B	5.66B	5.74B	5.28B
EBITDA	4.73B	3.90B	3.46B	2.72B	2.18B
Net Income	2.64B	2.19B	3.11B	2.39B	2.17B
Balance Sheet
Total Assets	38.02B	54.43B	41.22B	18.16B	15.46B
Cash, Cash Equivalents and Short-Term Investments	1.66B	2.33B	15.18B	1.81B	1.19B
Total Debt	12.18B	18.37B	14.04B	5.81B	5.99B
Total Liabilities	18.62B	27.65B	20.02B	9.74B	8.94B
Stockholders Equity	17.33B	23.72B	21.20B	8.38B	6.53B
Cash Flow
Free Cash Flow	1.51B	1.35B	1.90B	1.97B	1.16B
Operating Cash Flow	2.76B	3.87B	3.62B	3.65B	2.57B
Investing Cash Flow	-1.26B	-17.61B	-2.26B	-1.68B	-1.41B
Financing Cash Flow	-1.28B	677.92M	10.58B	-1.41B	-664.30M

CSL Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price85.10

Price Trends

50DMA

81.46

Positive

100DMA

79.76

Positive

200DMA

83.43

Positive

Market Momentum

MACD

1.56

Positive

RSI

52.75

Neutral

STOCH

33.10

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CSLLY, the sentiment is Neutral. The current price of 85.1 is below the 20-day moving average (MA) of 85.39, above the 50-day MA of 81.46, and above the 200-day MA of 83.43, indicating a neutral trend. The MACD of 1.56 indicates Positive momentum. The RSI at 52.75 is Neutral, neither overbought nor oversold. The STOCH value of 33.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CSLLY.

CSL Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CSLLY	77 Outperform	$82.40B	29.99	15.36%	1.57%	7.60%	9.47%
REGN	74 Outperform	$59.67B	14.19	15.34%	0.31%	5.38%	3.58%
ARGX	74 Outperform	$40.52B	31.09	24.75%	―	89.58%	―
VRTX	73 Outperform	$93.98B	26.20	22.77%	―	10.38%	―
BNTX	63 Neutral	$26.84B	―	-1.81%	―	7.51%	30.53%
ALNY	52 Neutral	$57.53B	―	-257.82%	―	5.01%	-330.09%
Sector *	51 Neutral	$7.35B	-0.20	-44.53%	2.35%	30.18%	-1.17%

* Healthcare Sector Average

Performance Comparison

CSLLY

CSL

85.10

-15.42

-15.34%

ALNY

Alnylam Pharma

438.93

168.75

62.46%

REGN

Regeneron

563.00

-555.00

-49.64%

VRTX

Vertex Pharmaceuticals

366.54

-97.97

-21.09%

ARGX

Argenx Se

661.83

123.66

22.98%

BNTX

BioNTech SE

111.66

31.04

38.50%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025